Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-26-036326
Filing Date
2026-08-06
Accepted
2026-08-06 15:45:05
Documents
13
Period of Report
2026-08-05
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A form8-ka.htm   iXBRL 8-K/A 42134
2 EX-3.3 ex3-3.htm EX-3.3 8687
3 EX-99.1 ex99-1.htm EX-99.1 31857
  Complete submission text file 0001493152-26-036326.txt   265391

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ensc-20260805.xsd EX-101.SCH 3011
5 XBRL LABEL FILE ensc-20260805_lab.xml EX-101.LAB 34915
6 XBRL PRESENTATION FILE ensc-20260805_pre.xml EX-101.PRE 22786
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 4390
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38306 | Film No.: 261248622
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)